|
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) Clinical research trials and The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC). The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) clinical trial. Subjects often receive the most expert healthcare possible for their The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
For Condition: Small Cell Lung Cancer
Status: Recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug that may enhance the effects of radiation therapy. Study patients will receive two additional courses of the standard chemotherapy combination after completing radiation therapy.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: (A patient must meet all of these criteria in order to qualify for study participation.) - Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with no prior radiotherapy. Patients are allowed to have had a resection or biopsy. - Women of reproductive potential must have a negative serum pregnancy test at the study screening visit. - Patients must give written informed consent to participate in the study. - Patients must be at least 18 years of age. - Patients must be able to take oral medication. - Patients should be completely recovered from recent surgery. - Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function. - Patients must be evaluated by the radiation oncologist prior to study entry. EXCLUSION CRITERIA: (A patient cannot meet any of these criteria in order to be eligible for study participation.) - Extensive Stage SCLC. - Women who are pregnant or lactating. - Use of an investigational drug within 30 days prior to the first dose of study medication. - Any medically/clinically significant active infection. - Symptoms of the SCLC spreading to the brain. - Patients with limited stage SCLC who have undergone complete resection with no measurable disease prior to starting chemotherapy. - Severe medical problems, unrelated to SCLC, that would limit the patient's full ability to follow all study rules and procedures, or that would expose the patient to extreme risk. - Other ongoing, immunotherapy or radiotherapy being administered at the time as study participation.
Total Enrollment:
Location and Contact Information:
Study Site *Recruiting*
Akron, Ohio, 44304
United States
Recruiting Study Coordinator 330-375-4221
Study Site *Recruiting*
Green Bay, Wisconsin, 54301-3508
United States
Recruiting Study Coordinator 920-433-8889
Study Site *Recruiting*
San Antonio, Texas, 78229-3900
United States
Recruiting Study Coordinator 210-616-5638
Study Site *Terminated*
Cincinnati, Ohio, 45219
United States
Terminated
Study Site *Recruiting*
Los Angeles, California, 90057
United States
Recruiting Study Coordinator 213-989-1888
Study Site *Recruiting*
Phoenix, Arizona, 85013
United States
Recruiting Study Coordinator 602-274-4484
Study Site *Recruiting*
New Orleans, Louisiana, 70112-2234
United States
Recruiting Study Coordinator 504-568-6291
Study Site *Terminated*
Elk Grove Village, Illinois, 60007
United States
Terminated
Study Site *Terminated*
Columbus, Ohio, 43222
United States
Terminated
Study Site *Recruiting*
Scarborough, Maine, 04074
United States
Recruiting Study Coordinator 207-885-7634
Study Site *Recruiting*
Springfield, Massachusetts, 01107
United States
Recruiting Study Coordinator 413-794-3736
Study Site *Recruiting*
Cincinnati, Ohio, 45219
United States
Recruiting Study Coordinator 513-751-4448
Study Site *Recruiting*
Robbinsdale, Minnesota, 55422
United States
Recruiting Study Coordinator 763-520-5847
Study Site *No longer recruiting*
Charlotte, North Carolina, 28204
United States
No longer recruiting
Study Site *Recruiting*
Minneapolis, Minnesota, 55455
United States
Recruiting Study Coordinator 612-624-5949
Study Site *Not yet recruiting*
Miami, Florida, 33136
United States
Not yet recruiting Study Coordinator 305-243-4180
Study Site *Terminated*
Cleveland, Ohio, 44195
United States
Terminated
Study Site *No longer recruiting*
Ft. Worth, Texas, 76104
United States
No longer recruiting
Study Site *Terminated*
Bethlehem, Pennsylvania, 19017
United States
Terminated
Study Site *Terminated*
LaJolla, California, 92037
United States
Terminated
Study Site *Recruiting*
New Orleans, Louisiana, 70121
United States
Recruiting Study Coordinator 504-842-4483
Study Site *Recruiting*
Lexington, Kentucky, 40536
United States
Recruiting Study Coordinator 859-257-3379
Study Site *Recruiting*
Madison, Wisconsin, 53792
United States
Recruiting Study Coordinator 608-262-8158
Study Site *Recruiting*
Gainesville, Florida, 32610-0383
United States
Recruiting Study Coordinator 352-265-0680
Study Site *Recruiting*
St. Louis, Missouri, 63141
United States
Recruiting Study Coordinator 314-523-5599
Study Site *Recruiting*
Indianapolis, Indiana, 46260
United States
Recruiting Study Coordinator 317-415-6631
Study Site *Recruiting*
La Crosse, Wisconsin, 54601-5494
United States
Recruiting Study Coordinator 608-775-2837
Study Site *Recruiting*
Little Rock, Arkansas, 72205
United States
Recruiting Study Coordinator 501-686-8274
Study Site *Recruiting*
Fountain Valley, California, 92882
United States
Recruiting Study Coordinator 714-210-2300
Study Site *Not yet recruiting*
Keene, New Hampshire, 03431
United States
Not yet recruiting Study Coordinator 603-354-5467
Study Site *Not yet recruiting*
Charlottesville, Virginia, 22908
United States
Not yet recruiting Study Coordinator 434-924-5226
Study Site *Terminated*
Tucson, Arizona, 85723
United States
Terminated
Study Site *Terminated*
Houston, Texas, 77030
United States
Terminated
Study Site *Recruiting*
Duluth, Minnesota, 55805
United States
Recruiting Study Coordinator 218-249-5337
Study Site *Recruiting*
Bakersfield, California, 93309
United States
Recruiting Study Coordinator 661-862-7178
Study Site *Terminated*
Columbia, Missouri, 65203
United States
Terminated
Study Site *Recruiting*
Greensboro, North Carolina, 27403-1199
United States
Recruiting Study Coordinator 336-832-0824
Study Site *Recruiting*
Wausau, Wisconsin, 54401
United States
Recruiting Study Coordinator 715-847-2353
Study Site *Recruiting*
Shreveport, Louisiana, 71103
United States
Recruiting Study Coordinator 318-212-8088
Study Site *Recruiting*
Cleveland, Ohio, 44106
United States
Recruiting Study Coordinator 216-844-1637
Study Site *Recruiting*
Toledo, Ohio, 43614
United States
Recruiting Study Coordinator 419-383-6583
Study Site *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Study Coordinator 314-747-1849
Study Site *Recruiting*
Albuquerque, New Mexico, 87109
United States
Recruiting Study Coordinator 505-243-4039
Study Site *Recruiting*
Milwaukee, Wisconsin, 53215
United States
Recruiting Study Coordinator 414-649-6093
Additional Information:
Study ID Numbers: 104864/535;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00043862
Other Small Cell Lung Cancer Studies:
1. Computed Tomography for Early Detection of Cancer in Women Who Are at Risk for Lung Cancer
2. INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer
3. The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
4. Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients with Sensitive Small Cell Lung Cancer (SCLC)
5. Inositol in Preventing Lung Cancer in Patients With Bronchial Epithelial Dysplasia Who Are Current or Former Smokers
Related Studies:
Other Small Cell Lung Cancer Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
|
|
|
|
|
|
|
|